TransMedics Group Inc. (TMDX)
TransMedics: Exceptional Q1 Undermines The Short Narrative
TransMedics reported extremely strong Q1 results, alleviating concerns from a weak Q3 2024 and a short attack in January. The company continues to expand its logistics capabilities and should see a boost from new heart and lung devices later in the year. While new perfusion devices are set to enter the market, TransMedics' competitive positioning appears to be extremely strong.
TransMedics Group, Inc. (TMDX) Q1 2025 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President & Chief Executive Officer Gerardo Hernandez - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Bill Plovanic - Canaccord Justin Wang - Morgan Stanley Chris Pasquale - Nephron Research Suraj Kalia - Oppenheimer David Rescott - Baird Mike Matson - Needham & Company Josh Jennings - TD Cowen Operator Good afternoon, and welcome to TransMedics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Compared to Estimates, TransMedics (TMDX) Q1 Earnings: A Look at Key Metrics
The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
TransMedics (TMDX) Tops Q1 Earnings and Revenue Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.35 per share a year ago.
Insights Into TransMedics (TMDX) Q1: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
TransMedics: The Financial Tipping Point That Will Drive Mass Adoption
TransMedics' NOP (National OCS Program) is revolutionizing organ transplantation, improving outcomes while reducing long-term healthcare costs. Insurance adoption is the key catalyst, with expanding reimbursement accelerating NOP's widespread use. Strong revenue growth, profitability, and upcoming catalysts support a $112 price target and a strong buy rating.
TransMedics Group Stock: A Millionaire-Maker in the Making?
TransMedics Group (TMDX 0.09%) once ranked among the hottest healthcare stocks around. Shares of the medical technology company delivered a gain of more than ninefold between the beginning of 2022 and late August of 2024.
1 Compelling Reason to Buy and Hold TransMedics Group Stock Forever
Donor organs make the difference between life and death for thousands of people every year. But there are two big problems.
TransMedics: A Very Bullish Last Few Months Could Change Sentiment
TransMedics Group, Inc. shows strong Q4 results with revenue at $121.6m and EPS at $0.2, beating estimates and reassuring investors. TMDX's long-term growth potential is supported by its innovative organ transplant technology and ambitious goals for increasing transplant volumes. Risks include margin expansion challenges, competition from cost-effective alternatives like NRP, and complexities in transitioning to an aviation logistics company.
1 Turnaround Growth Stock Down 60% That Could Double, According to Wall Street
With the recent market sell-off, now is potentially the time for investors to find their next big winner. After all, if one had invested in stocks during the bear markets of late 2018, the Covid drawdown of 2020, or the interest rate driven drawdown of 2022, you likely would have made out quite well.
Down 62%. Should You Buy TransMedics Stock on the Dip?
It's been a rough several months for TransMedics Group (TMDX -2.12%) shareholders. The stock has been beaten down by about 62% from the peak it set last August.
TransMedics: Aggressive Guidance Largely Ignored By The Market
TransMedics' stock has rebounded modestly in recent months on the back of a strong fourth quarter performance. Continued market growth and TransMedics return to gaining market share should help to boost investor confidence going forward. While TransMedics's share price remains well below all-time highs, its valuation still implies solid growth going forward.
